Home

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Search form

Historic company milestone reached in 1st US FDA approval of cannabidiol.
For investors/media, click here for more

Recent News

Aug 07, 2018
GW Pharmaceuticals plc Reports Fiscal Third Quarter 2018 Financial Results and Operational Progress
- Epidiolex® (cannabidiol) oral solution approved by FDA and on track to be launched in Fall - - Conference call today at 4:30 p.m. EST -  
Read more...
Jul 23, 2018
GW Pharmaceuticals to Report Third Quarter Financial Results and Host Conference Call on 7 August, 2018
London, UK, 23 July 2018: GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 August, 2018 its third quarter financial results for the period ending 30 June, 2018.
Read more...
Jun 25, 2018
GW Pharmaceuticals plc and its U.S. Subsidiary Greenwich Biosciences Announce FDA Approval of EPIDIOLEX® (cannabidiol) oral solution – the First Plant-derived Cannabinoid Prescription Medicine
- Approval for seizures associated with Lennox-Gastaut Syndrome or Dravet Syndrome, two rare, severe childhood-onset epilepsies -
Read more...
View More

Pharmaceutical Development Pipeline

Pharmaceutical Development Pipeline

  • Unpartnered
  • Partnered
  • Pre-Clinic
  • Phase 1
  • Phase 2
  • Phase 3
  • Submit
  • Approved

Epidiolex

Epidiolex
Dravet Syndrome
Approved
Epidiolex
Lennox-Gastaut Syndrome
Approved
Epidiolex
Tuberous Sclerosis
Phase 3

Sativex (U.S.)

Sativex
Ms Spasticity
Phase 3

CBDV (GWP42006)

GWP42006 (CBDV)
Epilepsy
Phase 2
GWP42006 (CBDV)
Autism Spectrum Disorders
Completed Phase 1

Other

GWP42003 (IV)
Neonatal Hypoxic-ischemic Encephalopathy
Phase 1
GWP42002 / GWP42003
Glioblastoma
Completed Phase 2
GWP42003
Schizophrenia
Completed Phase 2
Learn More